ADC Therapeutics SA (ADCT)

Market Cap	321.97M
Revenue (ttm)	66.75M
Net Income (ttm)	-214.91M
Shares Out	96.69M
EPS (ttm)	-2.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	308,664
Open	3.300
Previous Close	3.290
Day's Range	3.264 - 3.450
52-Week Range	0.360 - 6.040
Beta	1.59
Analysts	Strong Buy
Price Target	8.00 (+140.24%)
Earnings Date	Nov 5, 2024

About ADCT

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to contin...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 15, 2020
• Employees: 274
• Stock Exchange: NYSE
• Ticker Symbol: ADCT
• Website: https://www.adctherapeutics.com

Financial Performance

In 2023, ADC Therapeutics's revenue was $69.56 million, a decrease of -66.86% compared to the previous year's $209.91 million. Losses were -$240.05 million, 52.8% more than in 2022.

Analyst Forecast

According to 5 analysts, the average rating for ADCT stock is "Strong Buy." The 12-month stock price forecast is $8.0, which is an increase of 140.24% from the latest price.

Price Target

$8.0

(140.24% upside)

Analyst Consensus: Strong Buy